Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...

AstraZeneca has revealed that its top executive ... that the illegal imports could have involved cancer treatments Enhertu (trastuzumab deruxtecan), Imfinzi (durvalumab), or Imjudo (tremelimumab).

Maria joined AstraZeneca in 2017 as head of Respiratory, Inflammation & Autoimmunity in the Innovative Medicines and Early Development (IMED) Biotech Unit. In her role she leads early-stage ...

The Company History page lists out the major events in chronological order for AstraZeneca Pharma India Ltd. Company History - AstraZeneca Pharma India Ltd.